New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface ...

Biostar Pharmaceuticals plans to raise funds through an IPO on the Hong Kong Stock Exchange, offering 14.6 million shares at ...

Viking Therapeutics plans to advance its obesity drug VK2735 to Phase III trials by late 2024, following Phase II results ...

GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. The UK ...

Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

Intellia Therapeutics reported positive Phase II results for its CRISPR therapy NTLA-2002, showing an 81% reduction in ...

Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart ...

Orion has discontinued its pain management candidate ODM-111 due to a narrow therapeutic window found in toxicology studies.

Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines ...

Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.